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Granulicatella adiacens and Abiotrophia defectiva are an increasingly recognized cause of osteoarticular infections. We describe
two cases of G. adiacens and one case of A. defectiva native vertebral osteomyelitis (NVO) and review all published cases. Nine
cases of G. adiacens NVO and two cases of A. defectiva NVO were previously described. Patients were usually middle-aged men,
and classical risk factors for NVO were present in half of the cases. Concomitant bacteremia was reported in 78.6% of cases, and
concurrent infective endocarditis occurred in 36.4% of this sub-group of patients. Many different antibiotic schemes were
recorded, with median treatment duration of 6 weeks. In the most recent reports, glycopeptides represented the most frequent
empirical therapy, possibly due to the increasing emergence of G. adiacens and A. defectiva penicillin-resistant strains. Stabi-
lization surgery was rarely required (14.3% of cases), and clinical cure was generally achieved. In conclusion, Granulicatella spp.
and Abiotrophia spp. NVO is rare but increasingly described. A total antibiotic course of six weeks seems to be appropriate for
noncomplicated cases, and clinical outcome is generally favorable.
1. Introduction and Inclusion Criteria for
Case Definition
Granulicatella species and the related genus Abiotrophia are
Gram-positive lactic acid bacteria, previously referred to as
nutritionally variant streptococci because of their re-
quirement of L-cysteine or pyridoxal into culture media for
growth [1]. Granulicatella (formerly Abiotrophia) adiacens,
Abiotrophia defectiva, and Granulicatella elegans are parts of
the normal oropharyngeal, gastrointestinal, and urogenital
microflora but might also act as opportunistic pathogens [2].
Recently, thanks to 16S rRNA sequence analysis, Gran-
ulicatella para-adiacens (a species closely related to G.
adiacens) has also emerged as pathogenic for humans [3].
Usually considered a rare cause of infective endocarditis
(IE), G. adiacens, G. elegans, and A. defectiva account for
5–16% of all streptococcal IE cases [4, 5], even if the chal-
lenge in identification of these fastidious organismsmay lead
to underestimate the real incidence. Indeed, the pathogenic
role of G. adiacens and A. defectiva in osteoarticular in-
fections such as native vertebral osteomyelitis or spondy-
lodiscitis [6–15], prosthetic-related infections [16, 17], and
septic arthritis [18] is increasingly recognized.
Here, we described two cases of G. adiacens and one case
ofA. defectiva native vertebral osteomyelitis occurring in our
institution between 1 January 2008 and 1 December 2018.
We also reviewed all cases of native vertebral osteomyelitis
due to these organisms described in the medical literature.
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We searched PubMed articles written in English between 1
January 1990 and 1 December 2018 using a combination of
the following key words: “granulicatella,” “abiotrophia,”
“nutritionally variant streptococci,” “spondylodiscitis,” and
“vertebral osteomyelitis.” Moreover, in the Discussion sec-
tion, we summarize applicable guidelines and recent data
about G. adiacens and A. defectiva antibiotics susceptibility,
focusing on molecules of clinical utility in the setting of bone
infections.
2. Presentation of Institutional Cases
2.1. Case 1. In April 2017, a 50-year-old man with irrel-
evant past medical history started to report nocturnal low-
grade fever and low back pain. He empirically received a
short course of antibiotics but fever occasionally relapsed.
During the following weeks, the patient experienced
progressive dyspnea that led him to the local emergency
department (ED). At the arrival in the ED, the patient was
febrile (38.2°C), and his laboratory exams showed marked
leukocytosis (WBC � 22.9 G/μL, 77% neutrophils), mild
anemia (Hb � 10.6 g/dL), and increased C-reactive protein
(CRP � 11.2mg/dL).
A transthoracic echocardiography showed amassive aortic
insufficiency with evidence of multiple vegetations on the free
edge of the aortic cuspids. Two sets of blood cultures were
performed in the ED, and G. adiacens grew both from aerobic
and anaerobic blood bottles after 17 and 21hours in the first
set and after 17 and 22hours in the second set, respectively.
Blood cultures (BACT/ALERT FA Plus and BACT/ALERT
FN Plus) were processed using the BACT/ALERT system
(bioMe`rieux). Agar MHF for fastidious organism plates was
incubated in 5% CO2 at 35–37°C for 48 hours. Identification
was carried out by matrix-assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOFMS) using the
Vitek MS system (bioMerieux). Antimicrobial susceptibility
was performed by E-test method, and MICs were reported
according to PK-PD (nonspecies related) breakpoints as stated
in March 2017 EUCAST Clinical Breakpoints Tables [19]
(Figure 1(a)). 'ree days after ED admission, reparative aortic
surgery was performed in a local cardiac surgery unit. Sub-
sequently, the patient underwent a CT scan of the spine for
persistent back pain, and a diagnosis of L3-L4 native vertebral
osteomyelitis was made. 'e patient was transferred in May
2017 to our clinic to continue the antibiotic course. MRI of
the spine confirmed the L3-L4 native vertebral osteomyelitis
and showed similar degenerative changes also in L5-S1.
'e patient received a total of two-week intravenous course
of vancomycin 2 g/daily + ceftriaxone 2 g/daily + gentamicin
5mg/kg/daily, followed by intravenous ampicillin 12 g/daily
for two weeks. Patient’s clinical conditions improved, and he
was dischargedwith oral amoxicillin 4 g/daily for twoweeks. A
six-month follow-up MRI of the lumbar spine showed an
initial healing of the infectious process, and the patient re-
ported a significantly improvement of low back pain as well.
2.2.Case 2. A 47-year-old man was admitted to our clinic on
May 2017 with a 10-day history of fever and severe low back
pain after returning from a scuba diving session in Maldives.
His past medical history included hypertension and chronic
back pain due to L5 disc herniation. On examination,
body temperature was 38.5°C and blood pressure was 110/
80mmHg. Laboratory results showed a normal white cell
formula (WBC� 10.3G/μL, 79% neutrophils) and a raise of
C-reactive protein (CRP� 16.5mg/dL). Two sets of blood
cultures were performed at admission, and G. adiacens grew
both from aerobic and anaerobic blood bottles after 15 and
18 hours in the first set and after 16 hours in both aerobic
and anaerobic bottles of the second set. Blood cultures
(Bactec Plus Aerobic/F and Bactec Plus Anaerobic/F) were
processed using the BACTEC FX system (Becton Dickinson).
Identification and antimicrobial susceptibility (Figure 1(b))
were carried out as in Case 1.
A transthoracic echocardiography was negative for IE.
MRI of the spine showed an increased STIR signal change at
the L5-S1 level suggestive for early spondylodiscitis. To
determine if the morphostructural bone changes described
in MRI were metabolically active, a total body FDG-PET/CT
scan was performed: an intense L5-S1 standardized uptake
value (SUV� 7.1) was detected (see Figure 2) and diagnosis
of native vertebral osteomyelitis was made; no other met-
abolically active areas were detected. 'e patient started
empirically iv vancomycin 2 g/daily plus ceftriaxone 2 g/daily
for one week, and then switched to ceftriaxone alone for
3weeks. At discharge, the patient was switched to oral
amoxicillin 3 g/daily for 2weeks. A three-month clinical
follow-up was uneventful, with gradual pain reduction. 'e
patient fully recovered; no follow-up MRI was performed.
2.3. Case 3. In October 2018, a 75-year-old woman with
previous mitral valvuloplasty and previous breast cancer was
admitted in our clinic for persistent low back pain started
three months earlier without fever. An MRI of the spine
performed two days before admission showed a L4-L5 in-
fectious process. At the admission, blood tests showed amild
anemia (Hb� 9.5 g/dL) and a mild elevation of CRP
(CRP� 2.5mg/dL). A chest CT scan revealed a right pleural
effusion with bilateral parenchymal consolidation; a di-
agnostic thoracentesis was negative for microbial growth.
At day 15, the patient became feverish, and two sets of
blood cultures were performed. A. defectiva grew both from
aerobic and anaerobic blood bottles after 27 and 28 hours
in the first set and after 70 and 34 hours in the second
set, respectively. Blood cultures processing, microbiologi-
cal identification, and antimicrobial susceptibility were
carried out as in Case 1. 'e isolated A. defectiva strain
showed a reduced penicillin and ampicillin susceptibility
(Figure 1(c)); thus, a glycopeptide-based antibiotic regimen
was started. A transthoracic echocardiography showed a
severe mitral insufficiency without evidence of vegetations.
'e patient refused to perform a transesophageal echo-
cardiography. A FDG-PET/CT scan confirmed a localized
metabolic uptake at the L4-L5 level (SUV � 3.5); no other
metabolically active areas were detected.
'e patient received initially iv vancomycin 2 g/daily,
and then, she was transferred to a local cardiac surgery unit
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for mitral valve replacement. Because of initial renal failure,
after two weeks, the patient was switched to teicoplanin
400mg/daily according to the local infectious diseases
specialist’s consultation. Mitral valve culture was negative
for microbial growth. Surgical follow-up was uneventful,
and after three weeks, the patient was transferred to a cardiac
rehabilitation unit, where she completed a six-week course
of iv teicoplanin. At a six-month follow-up visit, the patient
reported an initial improvement of low back pain; no follow-
up MRI was performed.
3. Clinical Characteristics of Granulicatella
adiacens and Abiotrophia defectiva Native
Vertebral Osteomyelitis
During a ten-year period, we recorded in our institution two
cases of native vertebral osteomyelitis due toG. adiacens and
one due toA. defectiva.Other eleven cases of native vertebral
osteomyelitis due to these fastidious organisms were iden-
tified from PubMed search: nine due to G. adiacens [6–13]
and two due to A. defectiva [14, 15]. At the present, no cases
of G. elegans or G. para-adiacens spondylodiscitis have been
described.
G. adiacens and A. defectiva vertebral osteomyelitis
clinical characteristics and therapeutic regimens, including
our three cases, are shown in Table 1. Patients were pre-
dominantly males (78.5%) with a median age of 50.5 years
(IQR� 47.7–63.5). Many patients (8/14, 57.1%) presented
identifiable risk factors for native vertebral osteomyelitis
such as injecting drug use, infective endocarditis, de-
generative spinal disease, and diabetes mellitus.
As expected, all patients reported back pain; fever was
recorded in 9/14 cases (64.3%). Most nutritionally, variant
streptococci native vertebral osteomyelitis cases were as-
sociated with bacteremia (11/14 cases, 78.6%); meanwhile,
concurrent IE occurred only in a subgroup of these patients
(4/11, 36.4%).
Twelve different therapeutic schemes were recorded;
median antibiotic therapy duration was six weeks (IQR� 6-7),
ranging from to 4 to 15weeks. Surgical stabilization was
required in 2 out of 14 cases (14.3%). When outcome was
described (12 patients), clinical cure was achieved in all cases.
Antibiotics
Benzylpenicillin
Ampicillin
Ampicillin-
sulbactam
Ceriaxone
Rifampicin
Tetracycline
Teicoplanin
Vancomycin
Linezolid 2
≤0.016
≤0.016
0.125
0.004
≤0.002
≤0.016
≤0.016
≤0.002
MIC (μg/mL)
(a)
Benzylpenicillin
Ampicillin
Ampicillin-
sulbactam
Ceriaxone
Rifampicin
Tetracycline
Teicoplanin
Vancomycin
Linezolid
Antibiotics
2
≤0.016
≤0.016
0.125
0.004
≤0.002
≤0.016
≤0.016
0.064
MIC (μg/mL)
(b)
Benzylpenicillin
Ampicillin
Erythromycin
Clyndamycin
Levofloxacin
Teicoplanin
Vancomycin
Antibiotics
≤0.12
≤0.12
≤0.25
≤0.25
≥8
2
1
MIC (μg/mL)
(c)
Figure 1: Antibiograms and MICs of Granulicatella adiacens and Abiotrophia defectiva strains isolated from the clinical cases. (a) Case 1 G.
adiacens strain MICs. (b) Case 2 G. adiacens strain MICs. (c) Case 3 A. defectiva strain MICs.
Figure 2: FDG-PET/CT scan of patient 2 showing an
intense metabolic uptake between the lower plate of L5 and the
upper plate of S1.
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4. Discussion and Conclusions
Once known as nutritionally variant streptococci, G. adia-
cens and A. defectiva are a rare cause of native vertebral
osteomyelitis. Discrepancies still exist in terms of correct
taxonomic classification, being Granulicatella and Abio-
trophia terms used interchangeably even in recent articles
[9, 10, 13].
As expected, the clinical presentation of G. adiacens and
A. defectiva native vertebral osteomyelitis was back pain,
usually associated with fever. Patients with Granulicatella
and Abiotrophia spondylodiscitis were usually in their fifth
decade or older, and approximately half of cases presented
classical risk factors for spondylodiscitis such as endo-
carditis, intravenous drug using, or immunosuppressive
conditions. On the other hand, in a recent analysis, including
38 cases of G. adiacens endocarditis and 38 cases of A.
defectiva endocarditis, systemic embolism excluding the
central nervous system occurred in 9.4% and 11.8% of
patients for each group, respectively [5].
Usually, microbiological diagnosis of G. adiacens and A.
defectiva native vertebral osteomyelitis is made through blood
culturing and/or bone biopsy. Automatic biochemical test
systems, such as Vitek 2, are widely used in clinical practice,
but phenotypic characteristics alone may be inaccurate in
Granulicatella spp. and Abiotrophia spp. identification [20].
After the advent of 16S rRNA gene sequencing and MALDI-
TOF MS, identification within this group of fastidious bac-
teria have been made more readily and accurately performed
both at genus and species levels [21].
At the present, European EUCAST guidelines do not
provide specific recommendations on susceptibility testing
and MICs interpretation for Granulicatella and Abio-
trophia species and suggest the usage of PK-PD (nonspecies
related) breakpoints avoiding interpretation on suscepti-
bility [19]. As the vast majority of the European micro-
biology laboratories, our clinical microbiology laboratory
follows EUCAST guidelines, and disk diffusion tests and
E-tests are routinely performed for MIC determinations;
when indicated and in case of multidrug-resistant organ-
isms, broth microdilution method is used. On the contrary,
US CLSI guidelines, through the M45 Document on in-
frequently isolated or fastidious bacteria [22], give in-
dications on susceptibility testing and suggest
interpretative criteria for this class of microorganisms.
Indeed, most of the available data for Granulicatella spp.
and Abiotrophia spp. are based on CLSI indications. In
particular, using broth microdilution for MIC de-
termination as suggested in CLSI guidelines, differences in
terms of antimicrobial susceptibilities between the two
genera recently emerged [23–26]. In these studies, sus-
ceptibility ranged from 34 to 39% for penicillin, from 22 to
47% for ceftriaxone, and from 3 to 83% for cefepime for G.
adiacens strains. A. defectiva strains resulted less suscep-
tible to penicillin (range 10.8–24%) but more susceptible to
ceftriaxone (range 92–100%). On the contrary, the vast
majority of Granulicatella spp. and A. defectiva isolates
were fully susceptible to vancomycin, clindamycin, mer-
openem, and levofloxacin.
'us, in the setting of A. defectiva native vertebral os-
teomyelitis, a third-generation cephalosporin is still an
appropriate empiric therapy; meanwhile in case of G.
adiacens native vertebral osteomyelitis, an alternative par-
enteral agent such as a glycopeptide should be used while
antimicrobial susceptibility testing is pending. Agents with
high oral availability such as levofloxacin and clindamycin
may represent a good option for oral switch. Few data on
rifampin, daptomycin, and linezolid are available, and there
are no CLSI or EUCAST interpretive breakpoints for these
molecules. Elevated MIC50 and MIC90 for daptomycin and
linezolid were found in two different studies including
overall more than four hundred G. adiacens and more than
one hundred fifty A. defectiva isolates [23, 26]; therefore,
these two molecules should not currently be considered an
option.
Given the limited microbiological and clinical data and a
potential higher risk of complications, the American Heart
Association (AHA) and the European Society of Cardiology
(ESC) guidelines recommend a 4- to 6-week course of an-
tibiotics for the treatment of endocarditis due to G. adiacens
and A. defectiva [27, 28]. 'e suggested regimen combines
penicillin G, ampicillin, or ceftriaxone plus an amino-
glycoside for at least the first two weeks or vancomycin alone
in case of beta-lactam allergy as for enterococci infection.
'e “2015 Native Vertebral Osteomyelitis IDSA Guidelines”
do not expressly focus on nutritionally variant streptococci,
but antibiotic treatment can be similarly inferred from
enterococci and streptococcal infections, which in turn do
not substantially differ from AHA and ESC recommenda-
tions [29]. Of note, in the first case reports, initial antibiotic
therapy was penicillin based; in the last years, we observed a
greater tendency to prescribe a glycopetide-based antibiotic
regimen as empirical or definitive therapy. 'is may reflect
the increasing reporting of penicillin-resistant G. adiacens
strains. In our two cases, G. adiacens strains were susceptible
to penicillins; thus, after an initial empirical parenteral
therapy with vancomycin and ceftriaxone (plus gentamicin
in the case with IE), oral therapy with amoxicillin was
prescribed at discharge to conclude the antimicrobial course.
Radiological work-up of NVS native vertebral osteo-
myelitis generally included MRI imaging. In our patient 1,
MRI demonstrated a second infectious spine focus not
detected from a previous CTscan. However, in early stages of
native vertebral steomyelitis, bone and surrounding tissue
changes seen in MRI may be aspecific: in these cases, FDG-
PET/CT scan may be helpful to discriminate between a
chronic degenerative bone alteration and an early infectious
process [30], as well as in our patient two. In this latter case, a
negative transthoracic echocardiography along with the
absence of FDG-PET/CTuptakes in other sites, gave us a low
clinical suspicion of IE, and a transesophageal echocardi-
ography was not performed. Considering cases reported in
the literature, treatment duration ranged from 4 to 15weeks.
In our cases as well as in the most recent articles, G. adiacens
native vertebral osteomyelitis treatment duration has been
set to six weeks, presumably influenced both by the previous
cited 2015 native vertebral osteomyelitis IDSA guidelines,
and Bernard et al. randomized clinical trial on pyogenic
6 Case Reports in Infectious Diseases
native vertebral osteomyelitis treatment duration [31]. 'is
seems not to have affected the general favorable clinical
outcome observed in all cases, especially because compli-
cations as paravertebral abscesses or vertebral instability
requiring surgery occurred in two cases only.
In conclusions,Granulicatella andAbiotrophia species are
a rare but increasingly more recognized cause of osteo-
articular infections, including native vertebral osteomyelitis.
Blood isolation of the causative organism is frequent in this
setting, and native vertebral osteomyelitis may occur in the
absence of infective endocarditis. Considering data about
Granulicatella spp. and Abiotrophia spp. reduced suscepti-
bility to penicillins and cephalosporins, a glycopeptide-based
regimen may represent a therapeutic option while antimi-
crobial susceptibility testing is pending. Clinical outcome is
generally favorable, and noncomplicated cases of Gran-
ulicatella adiacens and Abiotrophia defectiva spondylodiscitis
can be effectively treated with a standard six-week course of
antibiotic therapy.
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